The Medicine Maker
VerifiedMagazine
The development and manufacture of small molecules, biologics, and advanced therapies draws on the talent, passion and experience of a wide range of professionals. At The Medicine Maker we bring those people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward.
The Medicine Maker team also brings you The Small Molecule Manufacturer, which celebrates the people, processes, and technologies transforming the development and manufacture of small molecule drugs. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United Kingdom |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesThe Manufacturing Questions Facing Chinese Biotech
China’s biopharma sector is moving rapidly beyond its traditional strengths in generics and domestic manufacturing, with growing numbers of companies pursuing globally competitive assets, international partnerships, and more sophisticated development strategies. As part of our ongoing series exploring the rise of China’s pharma market, we speak with Wayne Wen, Associate Director of Commercial Development at Lonza’s Nansha site, about the forces driving this transition.
CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
Patients own immune cells genetically modified in the laboratory, track down the disease driving B cells, even deep within tissues. Inflammatory foci such as those seen here around the knee joints of a study participant (magenta) are no longer detectable even several months after CD19-CAR T-cell therapy (right in the PET-MRI image). Swelling and pain have subsided, with improved mobility.
Musings from The Power List: Miguel Forte
What was your biggest professional highlight of the past 12 months? My leadership role in the field of cell and gene therapy as President of ISCT has been challenging, stimulating and rewarding. I have had the opportunity to help shape the field while contributing to the growth of ISCT by strengthening the Society's global presence and local impact.
Manufacturing Reality Behind Personalized Cancer Vaccines
Personalized cancer vaccines (PCVs) have changed the way we think about treating cancer. Instead of developing therapies for broad patient populations, these approaches are designed around the unique molecular profile of an individual patient's tumor. It’s one of the clearest examples that medicine is heading away from standardized treatment models and toward personalized therapies.
CAR T Before Surgery Improves Glioblastoma Control in Mice
Administering CAR T cells before glioblastoma surgery improved tumor control and survival compared with treatment after surgery in two mouse models. The study, led by researchers at the University of Geneva and Geneva University Hospitals, also identified surgery-induced changes in the tumor microenvironment that may restrict the effectiveness of postoperative immunotherapy. Surgical resection remains the first-line treatment for glioblastoma, followed by radiotherapy and chemotherapy.
Musings from The Power List: Peng Lu
Peng Lu What was your biggest professional highlight of the past 12 months? Over the past year, the most meaningful highlight for me has been advancing our late-stage clinical program in bradykinin-mediated angioedema across our Phase 3 programs, and reaching a key milestone with the readout of topline data from our RAPIDe-3 study of investigational deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.
What Will Drug Development Look Like in 2036?
Dajun Yang, Chairman & CEO, Ascentage Pharma Group International The boundary between small molecules and biologics will become obsolete so that the modality divide will no longer exist. Protein degraders, molecular glues, and other next-generation small molecule technologies are already reaching targets and mechanisms that were previously the exclusive domain of antibodies and cell therapies.
How Glycosylation Is Shaping Cancer Biomarker Discovery
Glycosylation is increasingly being recognized as an important layer of tumor biology, with relevance for cancer progression, immune interactions, and biomarker development. But the structural complexity of glycans, and the difficulty of studying them in tissue context, has historically limited their use in translational research.
China’s Biopharma Homecoming
For much of the past two decades, China’s biopharma industry was often viewed through the lens of fast-following, contract services, and manufacturing efficiency. But as Chinese companies move up the value chain, pursue more innovative programs, and attract growing interest from multinational pharma, the country’s role in global drug discovery is becoming harder to define in old terms.
This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement
Bristol Myers Ends Cellares Manufacturing Agreement Credit: “Bristol-Myers Squibb” by A 4, CC BY-SA 2.0 Bristol Myers Squibb has ended its partnership with Cellares for the commercial-scale manufacture of the CAR T-cell therapy Breyanzi. The companies signed an agreement worth up to $380 million in 2024, reserving manufacturing capacity in the US, European Union, and Japan.